Alumis
NASDAQ: ALMS6 known investors
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted oral therapies for immune-mediated diseases such as plaque psoriasis. Its precision drug-development approach is supported by a proprietary data analytics platform.